NYSE: DVADavita Inc Stock
$132.74-1.17 (-0.87%)
Updated Apr 24, 2024
DVA Price
$132.74
Fair Value Price
N/A
Market Cap
$11.64B
52 Week Low
$71.51
52 Week High
$141.54
P/E
17.42x
P/B
11.02x
P/S
0.78x
PEG
0.48x
Dividend Yield
N/A
Revenue
$12.14B
Earnings
$691.54M
Gross Margin
31.5%
Operating Margin
10.79%
Profit Margin
5.7%
Debt to Equity
13.4
Operating Cash Flow
$2B
Beta
0.7
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DVA Overview
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the U.S and internationally. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives unless they receive a donor kidney. Seventy percent of the company's revenues come from Medicare and other government-based health insurance programs. The company was founded in 1979 and is based in Denver, CO.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DVA ($132.74) is trading below its intrinsic value of $138.34, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DVA is good value based on its earnings relative to its share price (17.42x), compared to the US market average (41.27x)
P/E vs Market Valuation
DVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DVA due diligence checks available for Premium users.
Be the first to know about important DVA news, forecast changes, insider trades & much more!
DVA News
Valuation
DVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.42x
Industry
-2.13x
Market
41.27x
DVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.02x
Industry
4.61x
DVA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DVA price to earnings growth (PEG)
For valuing profitable companies with growth potential
DVA is good value based... subscribe to Premium to read more.
PEG Value Valuation
DVA's financial health
Profit margin
Revenue
$3.1B
Net Income
$150.7M
Profit Margin
4.8%
DVA's Earnings (EBIT) of $1.31B... subscribe to Premium to read more.
Interest Coverage Financials
DVA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.9B
Liabilities
$14.2B
Debt to equity
13.4
DVA's short-term assets ($3.14B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DVA's long-term liabilities ($11.51B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$485.2M
Investing
-$168.3M
Financing
-$403.2M
DVA's operating cash flow ($2.06B)... subscribe to Premium to read more.
Debt Coverage Financials
DVA vs Medical Care Facility Stocks
Davita Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.